BRAINSTORM CELL THERAPEUTICS INC. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>BRAINSTORM CELL THERAPEUTICS INC. filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>

AI Summary

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Filing is a 10-Q for the period ending March 31, 2024. Company name is BRAINSTORM CELL THERAPEUTICS INC. Incorporated in Delaware (DE). Business and mailing address is 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK, NY 10019. Fiscal year ends December 31.

Why It Matters

For investors and stakeholders tracking BRAINSTORM CELL THERAPEUTICS INC., this filing contains several important signals. This filing provides an update on the company's financial performance and operational status for the first quarter of 2024. Investors can review key financial metrics, risk factors, and business developments to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — BRAINSTORM CELL THERAPEUTICS INC. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would alter the risk profile based solely on the header information.

Analyst Insight

Review the full 10-Q filing for detailed financial statements, management discussion, and risk factors to understand the company's performance and outlook.

Key Numbers

• 20240331 — Period End Date (Conformed Period of Report)
• 20240514 — Filing Date (Filed as of Date)
• 1231 — Fiscal Year End (Fiscal Year End)

Key Players & Entities

• BRAINSTORM CELL THERAPEUTICS INC. (company) — Company Name
• BCLI (company) — Ticker Symbol
• 20240331 (date) — Conformed Period of Report
• 20240514 (date) — Filed as of Date
• DE (jurisdiction) — State of Incorporation
• 1325 AVENUE OF AMERICAS (address) — Business Address Street 1
• NEW YORK (location) — Business Address City
• 10019 (postal_code) — Business Address Zip

FAQ

Industry Context

BRAINSTORM CELL THERAPEUTICS INC. operates in the biotechnology sector, focusing on cell therapies.

Regulatory Implications

The company is subject to standard SEC reporting requirements for publicly traded companies, including the filing of quarterly reports (10-Q).

What Investors Should Do

1. Analyze the detailed financial statements within the 10-Q.
2. Review the Management's Discussion and Analysis for operational insights.
3. Examine the Risk Factors section for potential challenges and uncertainties.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-14: Filing Date — Date the 10-Q was officially filed with the SEC.

Year-Over-Year Comparison

This is the 10-Q filing for the period ending March 31, 2024, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $0.00005 — ange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market
• $1 — 40 ) * Represents an amount less than $1. The accompanying notes are an integr

Filing Documents

• bcli-20240331x10q.htm (10-Q) — 842KB
• bcli-20240331xex31d1.htm (EX-31.1) — 8KB
• bcli-20240331xex31d2.htm (EX-31.2) — 8KB
• bcli-20240331xex32d1.htm (EX-32.1) — 5KB
• bcli-20240331xex32d2.htm (EX-32.2) — 5KB
• 0001410578-24-000820.txt (&nbsp;) — 3256KB
• bcli-20240331.xsd (EX-101.SCH) — 27KB
• bcli-20240331_cal.xml (EX-101.CAL) — 27KB
• bcli-20240331_def.xml (EX-101.DEF) — 96KB
• bcli-20240331_lab.xml (EX-101.LAB) — 214KB
• bcli-20240331_pre.xml (EX-101.PRE) — 174KB
• bcli-20240331x10q_htm.xml (XML) — 377KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

– OTHER INFORMATION

PART II – OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 41 Item 5. Other Information 42 Item 6. Exhibits 43

SIGNATURES

SIGNATURES 44 3 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of March 31, 2024 U.S. DOLLARS IN THOUSANDS (Except share data and exercise prices) (UNAUDITED) 4 Table of Contents BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of March 31, 2024 U.S. DOLLARS IN THOUSANDS (Except share data and exercise prices) (UNAUDITED) INDEX Page Interim Condensed Consolidated Balance Sheets 6 Interim Condensed Consolidated Statements of Comprehensive Loss 7 Interim Condensed Statements of Changes in Stockholders' Equity (Deficit) 8 Interim Condensed Consolidated Statements of Cash Flows 10 Notes to Interim Condensed Consolidated Financial Statements 12 5 Table of Contents BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) March 31, December 31, 2024 2023 Unaudited Audited U.S. $ in thousands ASSETS Current Assets: Cash and cash equivalents $ 779 $ 1,300 Other accounts receivable 26 51 Prepaid expenses and other current assets (Note 4) 454 548 Total current assets $ 1,259 $ 1,899 Long-Term Assets: Prepaid expenses and other long-term assets $ 20 $ 22 Restricted Cash 182 185 Operating lease right of use asset (Note 5) 1,265 1,416 Property and Equipment, Net 622 686 Total Long-Term Assets $ 2,089 $ 2,309 Total assets $ 3,348 $ 4,208 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities: Accounts payables $ 4,690 $ 4,954 Accrued expenses 636 1,240 Operating lease liability (Note 5) 588 603 Employees related liability 917 1,003 Total current liabilities $ 6,831 $ 7,800 Long-Term Liabilities: Operating lease liability (Note 5) 533 672 Warrants liability (Note 6) 1,534

View Full Filing

View this 10-Q filing on SEC EDGAR